These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29019159)

  • 1. Alpha Lipoamide Ameliorates Motor Deficits and Mitochondrial Dynamics in the Parkinson's Disease Model Induced by 6-Hydroxydopamine.
    Zhou B; Wen M; Lin X; Chen YH; Gou Y; Li Y; Zhang Y; Li HW; Tang L
    Neurotox Res; 2018 May; 33(4):759-767. PubMed ID: 29019159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
    Bao XQ; Kong XC; Kong LB; Wu LY; Sun H; Zhang D
    Brain Res; 2014 Feb; 1547():49-57. PubMed ID: 24384139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MitoQ protects dopaminergic neurons in a 6-OHDA induced PD model by enhancing Mfn2-dependent mitochondrial fusion via activation of PGC-1α.
    Xi Y; Feng D; Tao K; Wang R; Shi Y; Qin H; Murphy MP; Yang Q; Zhao G
    Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2859-2870. PubMed ID: 29842922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
    Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
    Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway.
    Chu JM; Chen LW; Chan YS; Yung KK
    Neuropharmacology; 2011 Dec; 61(8):1389-98. PubMed ID: 21907219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotection by scorpion venom heat resistant peptide in 6-hydroxydopamine rat model of early-stage Parkinson's disease.
    Yin SM; Zhao D; Yu DQ; Li SL; An D; Peng Y; Xu H; Sun YP; Wang DM; Zhao J; Zhang WQ
    Sheng Li Xue Bao; 2014 Dec; 66(6):658-66. PubMed ID: 25516514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
    Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
    Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons.
    Misiak M; Beyer C; Arnold S
    Biochim Biophys Acta; 2010; 1797(6-7):1178-88. PubMed ID: 20416276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease.
    Guo X; Liu T; Zhao D; Wang X; Liu D; He Y; Shan C; Kong Y; Hu W; Tao B; Sun L; Zhao H; Li S; Liu J
    Neuroscience; 2017 Jul; 356():229-241. PubMed ID: 28504195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
    Zaitone SA; Abo-Elmatty DM; Shaalan AA
    Pharmacol Biochem Behav; 2012 Jan; 100(3):347-60. PubMed ID: 21958946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses.
    Kupsch A; Schmidt W; Gizatullina Z; Debska-Vielhaber G; Voges J; Striggow F; Panther P; Schwegler H; Heinze HJ; Vielhaber S; Gellerich FN
    J Neural Transm (Vienna); 2014 Oct; 121(10):1245-57. PubMed ID: 24627045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone.
    Van Laar VS; Berman SB; Hastings TG
    Neurobiol Dis; 2016 Jul; 91():247-61. PubMed ID: 27001148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
    Kim HG; Ju MS; Kim DH; Hong J; Cho SH; Cho KH; Park W; Lee EH; Kim SY; Oh MS
    Basic Clin Pharmacol Toxicol; 2010 Dec; 107(6):958-64. PubMed ID: 20629656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical effects of the R form of α-lipoic acid and its neuroprotective mechanism in cellular models of Parkinson's disease.
    Zhao H; Zhao X; Liu L; Zhang H; Xuan M; Guo Z; Wang H; Liu C
    Int J Biochem Cell Biol; 2017 Jun; 87():86-94. PubMed ID: 28390981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
    Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of mitochondrial dynamics by treadmill training to improve gait and mitochondrial deficiency in a rat model of Parkinson's disease.
    Chuang CS; Chang JC; Cheng FC; Liu KH; Su HL; Liu CS
    Life Sci; 2017 Dec; 191():236-244. PubMed ID: 28986095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
    Dabbeni-Sala F; Di Santo S ; Franceschini D; Skaper SD; Giusti P
    FASEB J; 2001 Jan; 15(1):164-170. PubMed ID: 11149904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.